LRRK2 G2385R Leucocyte and Urine Biomarker Study

NCT ID: NCT04436848

Last Updated: 2020-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-01

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Given the emerging evidence on LRRK2-related biomarkers, this project will focus on identifying leucocyte and urine biomarkers that are altered by the LRRK2 G2385R variant, and investigating the effects of LRRK2 kinase inhibitor (MLi-2) on these biomarkers, using immunoblotting and mass spectrometry.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PD patients positive for LRRK2 G2385R

This is a non-interventional study

Intervention Type OTHER

This is a non-interventional study

PD patients negative for LRRK2 G2385R

This is a non-interventional study

Intervention Type OTHER

This is a non-interventional study

Non-PD controls negative for LRRK2 G2385R

This is a non-interventional study

Intervention Type OTHER

This is a non-interventional study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

This is a non-interventional study

This is a non-interventional study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Parkinson's disease assigned by a movement disorder specialist according to clinical diagnostic criteria
* Age above 18 year-old
* Provision of a written informed consent

Exclusion Criteria

\- Physical or mental incapacity to complete study protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Michael J. Fox Foundation for Parkinson's Research

OTHER

Sponsor Role collaborator

University of Dundee

OTHER

Sponsor Role collaborator

Nextcea, Inc

UNKNOWN

Sponsor Role collaborator

Max Planck Institute of Biochemistry

UNKNOWN

Sponsor Role collaborator

University of Malaya

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ai Huey Tan, MD, FRCP

Role: PRINCIPAL_INVESTIGATOR

University of Malaya

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Malaya Medical Centre

Kuala Lumpur, , Malaysia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ai Huey Tan, MD, FRCP

Role: CONTACT

60379492891

Shen Yang Lim, MD, FRACP

Role: CONTACT

60379492891

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ai Huey Tan

Role: primary

60379492891

Shen Yang Lim

Role: backup

60379492891

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UMG2385R

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LRRK2 Mutation and Parkinson's Disease
NCT01424475 TERMINATED PHASE1
Chinese PD-LRRK2 Registry
NCT03523104 RECRUITING